SLC5A2 and atherosclerosis: The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin reduces cardiovascular (CV) mortality, all-cause mortality and heart failure (HF) hospitalization in patients with type 2 diabetes (T2DM) and established atherosclerotic CV disease (ASCVD) [1].